BOTHELL, Wash., Nov. 10, 2010 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (NYSE AMEX: DDD) today reported financial results for the three and nine months ended September 30, 2010.Stephen J. Turner, SCOLR Pharma's President and CEO, said, "Our focus for the remainder of the year will be to continue executing the plans for our extended release nutritional supplement and drug delivery businesses, which have both been advanced in the last quarter.
"We believe that our extended release formulations of nutritional products will offer consumers the benefits of these supplements on a continuous basis throughout the day, while also providing retailers an opportunity to provide their customers with greater choice. Working with the Emerson Group, we have been meeting with national retailers during their fourth quarter 2010 purchase planning cycles to present our nutritional products. Orders placed by these retailers in late 2010 or early 2011 would be expected to ship in early-mid 2011," Turner added.
Turner continued: "In the drug delivery business, we appear to be in the final stages of review by the Food and Drug Administration of our Abbreviated New Drug Application for extended release pseudoephedrine. Additionally, we have nearly completed protocol planning for the actual use label comprehension study for our extended release, 12-hour ibuprofen product. We expect to engage a services provider in the first quarter of 2011 in preparation for the conduct of that study. Additional revenue, financing or partnership support is required to complete the study, but we believe the Company is well positioned to move forward."
SCOLR Pharma also announced it was recently engaged by RedHill BioPharma, Ltd., to develop and test the manufacturing feasibility of prototype ondansetron tablets incorporating SCOLR's CDT technology. RedHill is an Isr
|SOURCE SCOLR Pharma, Inc.|
Copyright©2010 PR Newswire.
All rights reserved